Anti-PVRIG reference antibody (COM701) is used in immuno-oncology research to block the PVRIG (poliovirus receptor-related immunoglobulin domain) pathway, which plays a role in suppressing T-cell activity in the tumor microenvironment. By inhibiting this checkpoint, the antibody helps restore T-cell function, enhancing the immune system’s ability to target and destroy cancer cells. It serves as a reference standard in the development of PVRIG-targeted therapies, supporting assay calibration, potency testing, and comparative studies during biopharmaceutical development. Its use is primarily in preclinical and clinical research settings focused on novel combination immunotherapies, particularly alongside other checkpoint inhibitors like anti-PD-1 or anti-TIGIT antibodies, to evaluate synergistic anti-tumor responses.